These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 11181912

  • 1. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW, Cohen ML.
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM.
    Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
    Christopoulos A, Parsons AM, El-Fakahany EE.
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
    [Abstract] [Full Text] [Related]

  • 5. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine.
    Li Z, Snigdha S, Roseman AS, Dai J, Meltzer HY.
    Eur J Pharmacol; 2008 Oct 31; 596(1-3):89-97. PubMed ID: 18771666
    [Abstract] [Full Text] [Related]

  • 6. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
    Watson JM, Hunter AJ, Brown AM, Middlemiss DN.
    Eur J Pharmacol; 1999 Apr 01; 370(1):69-77. PubMed ID: 10323282
    [Abstract] [Full Text] [Related]

  • 7. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
    Christopoulos A, Pierce TL, Sorman JL, El-Fakahany EE.
    Mol Pharmacol; 1998 Jun 01; 53(6):1120-30. PubMed ID: 9614217
    [Abstract] [Full Text] [Related]

  • 8. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
    Grant MK, El-Fakahany EE.
    J Pharmacol Exp Ther; 2005 Oct 01; 315(1):313-9. PubMed ID: 16002459
    [Abstract] [Full Text] [Related]

  • 9. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
    Machová E, Jakubík J, El-Fakahany EE, Dolezal V.
    J Pharmacol Exp Ther; 2007 Jul 01; 322(1):316-23. PubMed ID: 17446301
    [Abstract] [Full Text] [Related]

  • 10. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, Riley GJ, Noy G, Orlek BS.
    J Pharmacol Exp Ther; 1997 Dec 01; 283(3):1059-68. PubMed ID: 9399977
    [Abstract] [Full Text] [Related]

  • 11. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
    De Lorme KC, Grant MK, Noetzel MJ, Polson SB, El-Fakahany EE.
    J Pharmacol Exp Ther; 2007 Dec 01; 323(3):868-76. PubMed ID: 17855477
    [Abstract] [Full Text] [Related]

  • 12. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
    Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA.
    Eur J Pharmacol; 2009 Jan 28; 603(1-3):147-9. PubMed ID: 19111716
    [Abstract] [Full Text] [Related]

  • 13. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
    Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN.
    Br J Pharmacol; 1999 Apr 28; 126(7):1620-4. PubMed ID: 10323594
    [Abstract] [Full Text] [Related]

  • 14. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, Swedberg MD, Suzdak PD, Sauerberg P.
    J Pharmacol Exp Ther; 1994 Apr 28; 269(1):271-81. PubMed ID: 7909557
    [Abstract] [Full Text] [Related]

  • 15. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset.
    Harries MH, Samson NA, Cilia J, Hunter AJ.
    Br J Pharmacol; 1998 May 28; 124(2):409-15. PubMed ID: 9641560
    [Abstract] [Full Text] [Related]

  • 16. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.
    DeLapp N, Wu S, Belagaje R, Johnstone E, Little S, Shannon H, Bymaster F, Calligaro D, Mitch C, Whitesitt C, Ward J, Sheardown M, Fink-Jensen A, Jeppesen L, Thomsen C, Sauerberg P.
    Biochem Biophys Res Commun; 1998 Mar 06; 244(1):156-60. PubMed ID: 9514902
    [Abstract] [Full Text] [Related]

  • 17. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.
    Jakubík J, Tucek S, El-Fakahany EE.
    J Pharmacol Exp Ther; 2004 Jan 06; 308(1):105-10. PubMed ID: 14569060
    [Abstract] [Full Text] [Related]

  • 18. Novel persistent activation of muscarinic M1 receptors by xanomeline.
    Christopoulos A, El-Fakahany EE.
    Eur J Pharmacol; 1997 Sep 03; 334(1):R3-4. PubMed ID: 9346340
    [Abstract] [Full Text] [Related]

  • 19. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, Werge T.
    Neuropsychopharmacology; 2003 Jun 03; 28(6):1168-75. PubMed ID: 12700711
    [Abstract] [Full Text] [Related]

  • 20. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
    Sheardown MJ, Shannon HE, Swedberg MD, Suzdak PD, Bymaster FP, Olesen PH, Mitch CH, Ward JS, Sauerberg P.
    J Pharmacol Exp Ther; 1997 May 03; 281(2):868-75. PubMed ID: 9152396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.